Member Info for Candid

After 3 months sitting around 10p this looks to be on the move, placing shares absorbed.

The advanced Tiris project is the focus but we’ll also see a scoping study on Haggan in Sweden in Q3, remember that’s not just a uranium project but a huge vanadium and critical metals resource.

Definitely the Rudd effect, he’s widely respected in the City so a real coup to see him taking the Chairman’s role, he wouldn’t return if he didn’t see good potential here.

Rudd and Covey may well be buying if the dealing window is open but more likely funds and investors returning after the sell-off after the previous CEO departure.

Remember when the Conviction Life Sciences fund had this as one of their top picks? That fund didn’t launch in the end but I’m sure the same group of investors are finding other ways to accumulate here.

Well done on those who bought or added at sub 30p levels

This team are set to deliver: Sir Nigel Rudd, Chris Tovey, Dr Debra Barker, Dr William Love, Susan Koppy plus the well connected NEDs and Scientific Advisory board.

Well funded, strong pipeline, partnerships & deals will come.

This is a highly experienced and successful pharma executive, a great appointment. This board now looks re-energised and set to make a big impact to deliver value for Destiny’s pipeline. I don’t think the company will now get snapped up on the cheap which was a likely scenario, it’s very well positioned to add substantial value as deals are finalised.

Yes maybe seller is out now and overhang cleared. The PGM plays have been in a downward pressure for months now, weak palladium and platinum prices, but a turnaround will come when the cycle turns.

What if there is a good hit on the current nickel sulphide drilling??? this would rocket.

Following is a report from FnArena. I think it’s worth keeping a close eye on Sweden’s stance on mining, the current government is in favour of overturning the uranium moratorium - this would unlock significant value at Aura’s Haggan project (the 2nd biggest uranium resources in the world and in addition one of the world’s biggest vanadium deposits)

“The Swedish parliament this week adopted a new energy target, which gives the new conservative government approval to advance plans to build new nuclear power plants. The new target sets a goal to have "100% fossil-free” electricity instead of “100% renewable”.

This is a key element of the government’s plan to meet forecast electricity demand by 2040 and reach net-zero emissions by 2045. The government supports new reactors that are essential for the shift to a fossil-free economy. Today, nuclear power provides about 40% of Sweden's current electricity supply.

But for those assuming a new source of uranium demand is opening up, Sweden also has aspirations on the other side of the equation.

Sweden boasts the European Union's largest uranium reserves but mining is not permitted. With new investments in nuclear power, the government wants to change the law.

Canadian-listed District Metals Corp last week reported its Swedish subsidiary has received approval for a mineral license application to explore for copper, molybdenum, zirconium, and rare earth elements in northern Sweden. The Ardnasvarre Property hosts several uranium, lead-zinc-silver, and copper mineralised occurrences.

In addition, Australian-listed Aura Energy is working to enable the granting of an exploitation permit for its polymetallic Haggan Project in Sweden, which includes uranium resources.”

When an investment professional buys for their personal portfolio then you know you’re in good company.

He’s on the board of the Fidelity China Special Situations Trust amongst other directorships:

https://investment-trusts.fidelity.co.uk/fidelity-china-special-situations/?p=0&c=10

I’ve added on the news today, SPOR-COV is early stage but this has huge potential.
DEST now has 3 significant ‘company-maker’ treatments in clinical trials and it’s still trading at ‘in vitro’ levels

Stunning deal, Helge has played a blinder here, this has exceeded my expectations, now the future looks very exciting, production and exploration possibilities with serious financial backing

Will be interesting to see if FDA approves SER-109 (Seres Therapeutics), the decision is on Wednesday 26th.
This is a rCDI treatment that's further down the development stage than DEST's NTCD-M3. I think a positive outcome will also be good for NTCD-M3 as it paves the way for similar treatments. I'm half temped to take a punt on Seres Therapeutics ahead of the decision but sometimes you just don't know with FDA, plus it's a first microbiome approval so quite pivotal.

This is quite extraordinary, Katherine is the President and CEO of the world’s wealthiest art foundation and she steps into a director role here at HELD?
obviously she must be strong believer in the medicinal use of cannabis and a big supporter of Greece development. Can we we see a grant or financing deal heading this way soon?
Watching with interest..

Any news here? Huge volume on Nasdaq

I believe Seres is our nearest competitor in the field of Recurrent CDI treatment, they are a bit further down the line with their development (completed Phase III with positive, but I would say with not that amazing topline results, 27% reduction in recurrence). I would say M3 is far superior from phase II results.
Anyway, just pointing out the partnering deal that they completed with Aimmune Therapeutics (Nestle Health arm), $175m upfront payment, a further $125m on an FDA approval and additional $225m milestone targets on sales. Total $500m upfront and 50% of commercial profits.

https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-nestle-health-science-announce-ser-109-co

Over 60% of shares held by cornerstone investors and insiders, Odey Asset Management top the list with 18.4%, any other funds who want in will drive this valuation much higher.

Good to see the coverage, this needs publicity, often UK innovation and research does not get enough coverage, the US are much better at promoting and attracting investment. Lets hope this gets some overseas media time too.
This is just the start for EpiSwitch, many more potential use cases are possible.

Aimmune Therapeutics inc

There's also Immune Inc (a Nestle Health Science company), which are already collaborating with Seres Therapeutics on their upcoming review of thier live microbiome therapeutic.
Makes sense for majors who are already leading research in this field to have a multi pronged approach.

There’s a few global multinationals who already have some experience in CDI drug research and development, one very familiar name beginning with P.
Also makes sense for another multinational beginning with F who have recently had an FDA approved CDI treatment and would be very keen to complement it with Destiny’s product which is potentially superior.

Superb news on a very significant new use of OBD’s Episwitch platform. This blood test has the potential for huge cost savings for hospitals not only in the UK, but globally.
Well done OBD team on a successful clinical collaboration and a peer reviewed publication.

Any thoughts on what US pharma have the knowledge/experience in this field and would be keen to lead on the M3 asset? I think this will be very attractive to most of the big US pharmas.

Putting it into context:
“C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United States and it causes approximately 55 deaths a day. In the elderly population, 1 in 11 individuals over the age of 65 die within the month after being infected. The infection has a high recurrent rate, about 1 in 6 patients who get C. diff will get it again within 2-8 weeks.

Results being shown by DEST in preventing recurrence -- the major cause of C. diff morbidity and mortality, and the principal contributor to C. diff’s $4.5 billion annual cost to the US healthcare system.
Being able to reduce or eliminate recurrence would be a game-changing development in treating an infection that affects so many individuals, especially amid rising bacterial resistance to antibiotic (vancomycin). Antibiotics do not kill dormant C. difficile spores nor address the disrupted microbiome, the underlying cause of recurrent disease”